medicationPrescription only (US)FDA-approved and EMA-authorized for major depressive disorder and related anxiety disorders; prescription-only
VenlafaxineBenefits, Dosage & Interactions
Also known as: Effexor
Venlafaxine is an antidepressant medication belonging to the serotonin-norepinephrine reuptake inhibitor (SNRI) class. It is primarily used to treat major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder (SAD), and panic disorder (PD) (MedlinePlus). It is typically taken in the morning.
How much Venlafaxine do people take?
Doses examined across the antidepressant trials pooled in the cited network meta-analysis ranged from about 75 mg/day up to 375 mg/day for extended-release venlafaxine. Route reported: Oral, as immediate-release or extended-release tablets/capsules. Frequency reported: Once daily for extended-release formulations, or divided doses for immediate-release, per the label literature referenced. These are amounts documented in the cited studies and labels for Venlafaxine — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
See the full reported protocol and its sourcesResearched by DoseRoutine Research TeamReviewed for accuracy by Nicholas Alexander, RSE, SO, PMPLast updated Educational reference only — not medical advice. Always confirm dosing and safety decisions with a licensed clinician.
Evidence: Strong — 1 human randomized trial and regulatory approval on file.
Evidence strengthStrong · 4/4
PreclinicalStrong human evidence
1 human randomized trial and regulatory approval on file.
How is venlafaxine different from an SSRI?
Venlafaxine is an SNRI, affecting serotonin and norepinephrine pathways rather than being classified as an SSRI. The formulation and indication matter, and response cannot be predicted simply from another antidepressant working or failing.
Source: MedlinePlus: Venlafaxine
Browse compound evidence cardsPlasma half-life
~5 h
Typical timing
in the morning
Food rule
with food
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Reported amounts
- Doses examined across the antidepressant trials pooled in the cited network meta-analysis ranged from about 75 mg/day up to 375 mg/day for extended-release venlafaxine[1]
- Route studied
- Oral, as immediate-release or extended-release tablets/capsules[1]
- Frequency
- Once daily for extended-release formulations, or divided doses for immediate-release, per the label literature referenced[1]
- Cycle length
- Acute treatment phases of roughly 6–12 weeks in the trials pooled by the cited meta-analysis, with longer maintenance use common in practice[1]
- Half-life
- Approximately 5 hours for venlafaxine and about 11 hours for its active metabolite, as reported in the pharmacologic literature[1]
Reported for Venlafaxine in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Venlafaxine entry is written from. Each number matches an inline marker above.
- [1]Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysisCipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y · The Lancet · 2018 · Peer-reviewed · PMID 29477251
- [2]Sequenced treatment alternatives to relieve depression (STAR*D): rationale and designRush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA · Controlled Clinical Trials · 2004 · Peer-reviewed · PMID 15061154
References & Evidence
Sources on this page that document Venlafaxine dosing, timing and safety.
- [1]U.S. National Library of Medicine View source
- [2]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Venlafaxine?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Venlafaxine is an antidepressant medication belonging to the serotonin-norepinephrine reuptake inhibitor (SNRI) class. It is primarily used to treat major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder (SAD), and panic disorder (PD) (MedlinePlus). It is also sometimes used off-label for other conditions like neuropathic pain and hot flashes (DrugBank). Venlafaxine is available in immediate-release (IR) and extended-release (ER) formulations. The ER formulation is often preferred due to its once-daily dosing and potentially better tolerability profile compared to the IR version, which typically requires multiple daily doses (FDA label). As a prescription medication, its use is directed by a licensed clinician.
What does the research say about Venlafaxine?
Tap a section to expand.
Venlafaxine exerts its therapeutic effects by inhibiting the reuptake of two key neurotransmitters in the brain: serotonin and norepinephrine (DrugBank). It has a weaker effect on dopamine reuptake. By blocking the reuptake pumps for these neurotransmitters, venlafaxine increases their concentration in the synaptic cleft, the space between nerve cells. This increased availability of serotonin and norepinephrine is thought to modulate neuronal activity, leading to improvements in mood, anxiety, and other symptoms associated with conditions like depression and anxiety disorders (PubChem). The reuptake inhibition of serotonin is prominent at lower doses, while norepinephrine reuptake inhibition becomes more pronounced at higher doses (Examine.com). Unlike some older antidepressants, venlafaxine has relatively low affinity for muscarinic, histaminergic, or alpha-1 adrenergic receptors, which contributes to a more favorable side effect profile compared to tricyclic antidepressants (DrugBank).
Source for this section: Sources for How does Venlafaxine work?: Jumps to this entry in the sources and references list at the end of the page.
Venlafaxine has demonstrated efficacy in the treatment of several mental health conditions. For major depressive disorder (MDD), it has been shown to reduce depressive symptoms, including low mood, anhedonia (loss of interest or pleasure), sleep disturbances, and fatigue (Cochrane). In the context of generalized anxiety disorder (GAD), venlafaxine has been found to alleviate excessive worry, tension, and other anxiety-related symptoms (MedlinePlus). It is also an effective treatment for social anxiety disorder (SAD), helping to reduce fear and avoidance in social situations, and for panic disorder (PD), where it can decrease the frequency and severity of panic attacks (DrugBank). Beyond its primary indications, some clinicians may use venlafaxine off-label for the management of neuropathic pain, such as diabetic neuropathy, due to its norepinephrine reuptake inhibitory properties (Examine.com). It has also been studied for its potential to reduce the severity and frequency of hot flashes, particularly in women experiencing menopause (Mayo Clinic). Its extended-release formulation allows for once-daily dosing, which can improve adherence to treatment (FDA label).
Numerous randomized controlled trials and meta-analyses support the efficacy of venlafaxine in its approved indications. For major depressive disorder, a Cochrane review found that venlafaxine was more effective than placebo and comparable to or slightly more effective than some other antidepressants for acute treatment (Cochrane). In generalized anxiety disorder, evidence from multiple clinical trials has shown venlafaxine to be superior to placebo in reducing GAD symptoms (MedlinePlus). Similarly, for social anxiety disorder and panic disorder, controlled studies have demonstrated its effectiveness in alleviating symptoms compared to placebo (DrugBank). Its use in neuropathic pain is supported by some clinical data suggesting benefits, particularly in conditions like painful diabetic neuropathy (Examine.com). For menopause-related hot flashes, studies have shown venlafaxine can reduce the frequency and intensity of hot flashes, though it is not an FDA-approved indication for this use (Mayo Clinic). The long-term efficacy and safety of venlafaxine have been established through follow-up studies extending over several months to a year (FDA label).
Common side effects of venlafaxine can include nausea, headache, insomnia, dizziness, dry mouth, sweating, constipation, and sexual dysfunction (MedlinePlus). Some individuals may experience dose-related increases in blood pressure, particularly at higher doses (DrugBank). Nausea is often transient and tends to improve with continued use. Sleep disturbances, such as insomnia or drowsiness, can occur. Sexual dysfunction, including decreased libido, delayed ejaculation, or anorgasmia, is a frequently reported side effect of many antidepressants, including venlafaxine. Less common but more serious side effects can include serotonin syndrome (especially when combined with other serotonergic agents), increased risk of bleeding, and angle-closure glaucoma (FDA label). If any side effects are severe or persistent, a qualified clinician should be consulted. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Source for this section: Sources for What are the side effects of Venlafaxine?: Jumps to this entry in the sources and references list at the end of the page.
Venlafaxine carries a boxed warning regarding an increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults (up to 24 years of age) when taking antidepressants (FDA label). Close monitoring for worsening depression, suicidality, or unusual changes in behavior is crucial, especially during initial treatment or dose adjustments. Venlafaxine should be used with caution in patients with a history of heart disease, hypertension, or hyperlipidemia, as it can cause dose-related increases in heart rate and blood pressure (DrugBank). It can also cause or exacerbate hyponatremia (low sodium levels), especially in elderly patients or those taking diuretics. Patients with a history of seizures should be carefully monitored. Abrupt discontinuation of venlafaxine can lead to withdrawal symptoms (discontinuation syndrome), which can include dizziness, nausea, headache, paresthesias (electric shock-like sensations), vivid dreams, and anxiety (MedlinePlus). Therefore, discontinuation should always be gradual and under the supervision of a clinician. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Source for this section: Sources for Who should avoid Venlafaxine?: Jumps to this entry in the sources and references list at the end of the page.
Venlafaxine is contraindicated in patients with known hypersensitivity to venlafaxine hydrochloride or to any excipient in the formulation (FDA label). It is also contraindicated in patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI, due to the risk of serious, potentially fatal, serotonin syndrome (DrugBank). Conversely, at least 7 days should elapse after discontinuing venlafaxine before starting an MAOI. Patients with uncontrolled narrow-angle glaucoma should avoid venlafaxine due to the risk of angle-closure glaucoma. Caution is advised in patients with severe uncontrolled hypertension or a recent history of myocardial infarction or unstable heart disease (MedlinePlus). This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Source for this section: Sources for When should Venlafaxine not be taken?: Jumps to this entry in the sources and references list at the end of the page.
Combining venlafaxine with monoamine oxidase inhibitors (MAOIs) is strictly contraindicated due to the high risk of serotonin syndrome, a potentially life-threatening condition (FDA label). Other medications that increase serotonin levels, such as other SSRIs, SNRIs, tricyclic antidepressants, triptans (for migraines), tramadol, fentanyl, lithium, buspirone, amphetamines, and St. John's Wort, should be used with extreme caution with venlafaxine, as they can also increase the risk of serotonin syndrome (MedlinePlus). Concurrent use with antiplatelet agents or anticoagulants (e.g., warfarin, aspirin, NSAIDs) can increase the risk of bleeding (DrugBank). Venlafaxine is metabolized by the CYP2D6 enzyme; therefore, co-administration with strong CYP2D6 inhibitors (e.g., quinidine, fluoxetine, paroxetine) may increase venlafaxine levels, while CYP2D6 inducers may decrease its efficacy (Examine.com). Alcohol consumption should be avoided or significantly limited while taking venlafaxine, as it can worsen central nervous system depression and increase side effects (Mayo Clinic). This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Source for this section: Sources for What should you not mix with Venlafaxine?: Jumps to this entry in the sources and references list at the end of the page.
Venlafaxine is typically taken once daily, preferably in the morning, along with food. Taking it with food can help reduce gastrointestinal upset such as nausea (FDA label). The extended-release (ER) formulation is designed for once-daily administration. It is important to swallow the extended-release capsules whole with fluid; they should not be chewed, crushed, or dissolved (MedlinePlus). Consistent timing of administration each day can help maintain stable drug levels in the body.
Source for this section: Sources for When should you take Venlafaxine?: Jumps to this entry in the sources and references list at the end of the page.
Put it into practice
Reading about Venlafaxine is the first step — DoseRoutine helps you act on it. These free tools turn what you just learned into a routine.
What interacts with Venlafaxine?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any supplement + medication | Note | Category ruleConfidence: theoretical | Some supplements change how the body processes medications (absorption, liver enzymes, or additive effects).Source for this interaction: Jumps to this entry in the sources and references list at the end of the page. | Specific pairs are checked against a licensed drug database and shown with their own severity. Always confirm with your provider or pharmacist. |
| Any vitamin + medication | Note | Category ruleConfidence: theoretical | Certain vitamins interact with specific medications (e.g., vitamin K with blood thinners).Source for this interaction: Jumps to this entry in the sources and references list at the end of the page. | Specific pairs are checked against a licensed source; confirm with your provider. |
| Phenelzine | Avoid | Compound pairConfidence: theoretical | Combining SSRIs/SNRIs with MAOIs can cause life-threatening serotonin syndrome.Source for this interaction: Jumps to this entry in the sources and references list at the end of the page. | Do not combine. Allow at least 14 days between stopping one and starting the other (5 weeks for fluoxetine). |
| Tranylcypromine | Avoid | Compound pairConfidence: theoretical | Combining SSRIs/SNRIs with MAOIs can cause life-threatening serotonin syndrome.Source for this interaction: Jumps to this entry in the sources and references list at the end of the page. | Do not combine. Allow at least 14 days between stopping one and starting the other (5 weeks for fluoxetine). |
| Selegiline | Avoid | Compound pairConfidence: theoretical | Combining SSRIs/SNRIs with MAOIs can cause life-threatening serotonin syndrome.Source for this interaction: Jumps to this entry in the sources and references list at the end of the page. | Do not combine. Allow at least 14 days between stopping one and starting the other (5 weeks for fluoxetine). |
| Rasagiline | Avoid | Compound pairConfidence: theoretical | Combining SSRIs/SNRIs with MAOIs can cause life-threatening serotonin syndrome.Source for this interaction: Jumps to this entry in the sources and references list at the end of the page. | Do not combine. Allow at least 14 days between stopping one and starting the other (5 weeks for fluoxetine). |
| 5-HTP | Avoid | Compound pairConfidence: theoretical | 5-HTP raises serotonin and layered onto an SSRI/SNRI risks serotonin syndrome.Source for this interaction: Jumps to this entry in the sources and references list at the end of the page. | Avoid combining 5-HTP with prescription serotonergic antidepressants. |
| L-Tryptophan | Caution | Compound pairConfidence: theoretical | Additional serotonin precursor with an SSRI/SNRI can push serotonin too high.Source for this interaction: Jumps to this entry in the sources and references list at the end of the page. | Do not combine without a prescribing clinician's guidance. |
| St John's Wort | Avoid | Compound pairConfidence: theoretical | St John's Wort has serotonergic activity and induces CYP3A4, altering SSRI levels.Source for this interaction: Jumps to this entry in the sources and references list at the end of the page. | Avoid combining. |
Frequently asked questions about Venlafaxine
Venlafaxine is the generic name for the active ingredient, while Effexor is the brand name under which it was originally marketed. Both refer to the same medication.
While some patients may notice improvements within a week or two, it generally takes several weeks (typically 4-6 weeks) to experience the full antidepressant or anxiolytic effects of venlafaxine (MedlinePlus). It is important to continue taking the medication as prescribed, even if immediate results are not apparent.
No, abrupt discontinuation of venlafaxine is not recommended due to the risk of withdrawal symptoms, also known as discontinuation syndrome. Symptoms can include dizziness, nausea, agitation, headache, and electric shock-like sensations (DrugBank). If you need to stop venlafaxine, your clinician will guide you through a gradual tapering process.
If you miss a dose of venlafaxine, take it as soon as you remember unless it is almost time for your next scheduled dose. In that case, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one (Mayo Clinic). Always consult your clinician or pharmacist for personalized advice.
Weight changes can occur with many antidepressants, including venlafaxine. Some individuals may experience weight gain, while others may experience weight loss or no significant change (Examine.com). If you are concerned about weight changes, discuss them with your clinician.
Venlafaxine is a medication, and interactions are possible with prescriptions, hormones, peptides and other supplements in the same routine. Because Venlafaxine is usually taken in the morning, most avoidable conflicts come from what else lands in that same window. With a reported plasma half-life near 5 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Venlafaxine with no sign-up.
Combining a medication like Venlafaxine with TRT is usually a question of labs rather than a blanket yes or no: the ester, injection interval and any aromatase inhibitor all change the answer. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Each peptide class carries its own profile against Venlafaxine: a healing peptide raises different questions than a GLP-1 agonist or a growth-hormone secretagogue. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
A short plasma half-life of roughly 5 hours is why protocols often split Venlafaxine across the day rather than using a single dose. It is typically taken in the morning. Most protocols have it taken with food. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
For Venlafaxine the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Venlafaxine is an SNRI, affecting serotonin and norepinephrine pathways rather than being classified as an SSRI. The formulation and indication matter, and response cannot be predicted simply from another antidepressant working or failing.
Abrupt discontinuation can cause withdrawal symptoms. A prescriber should guide changes; worsening mood or suicidal thoughts also require prompt attention, especially in younger people and around treatment changes.
Doses examined across the antidepressant trials pooled in the cited network meta-analysis ranged from about 75 mg/day up to 375 mg/day for extended-release venlafaxine. Route reported: Oral, as immediate-release or extended-release tablets/capsules. Frequency reported: Once daily for extended-release formulations, or divided doses for immediate-release, per the label literature referenced. These are amounts documented in the cited studies and labels for Venlafaxine — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
Which studies looked at Venlafaxine?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine.(opens PubMed in a new tab)Depression and anxiety · 2000 · PMID 11098412 · https://pubmed.ncbi.nlm.nih.gov/11098412/
- 2.Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis(opens PubMed in a new tab)Lancet Psychiatry · 2019 · PMID 31178367 · https://pubmed.ncbi.nlm.nih.gov/31178367/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- MedlinePlus(opens in a new tab)U.S. National Library of Medicine · medlineplus.gov/druginfo/meds/a694020.html
- PubChem CID 9795857(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/9795857
Verify at
Publisher search links for Venlafaxine. These are places to check the information — they are not citations, so they are not numbered.
- Cochrane Library(publisher search, opens in a new tab)Cochrane · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- Examine.com(publisher search, opens in a new tab)Examine.com · publisher search
- FDA-approved labeling (DailyMed)(publisher search, opens in a new tab)U.S. Food and Drug Administration · publisher search
- Mayo Clinic(publisher search, opens in a new tab)Mayo Clinic · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Venlafaxine?
Plain-text summary, safe to quote verbatim:
Venlafaxine is an antidepressant medication belonging to the serotonin-norepinephrine reuptake inhibitor (SNRI) class. It is primarily used to treat major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder (SAD), and panic disorder (PD) (MedlinePlus). It is typically taken in the morning.
Source: DoseRoutine — https://doseroutine.com/library/venlafaxine
Venlafaxine cheat sheet
DoseRoutine cheat sheet · Medication
Venlafaxine
Venlafaxine is an antidepressant medication belonging to the serotonin-norepinephrine reuptake inhibitor (SNRI) class. It is primarily used to treat major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder (SAD), and panic disorder (PD) (MedlinePlus).
Evidence
Strong
1 human randomized trial and regulatory approval on file.
Studied range
Doses examined across the antidepressant trials pooled in the cited network meta-analysis ranged from about 75 mg/day up to 375 mg/day for extended-release venlafaxine
Route
Oral, as immediate-release or extended-release tablets/capsules
Frequency studied
Once daily for extended-release formulations, or divided doses for immediate-release, per the label literature referenced
Half-life
~5 h
Timing
in the morning
With food
with food
Prescription only (US)FDA-approved and EMA-authorized for major depressive disorder and related anxiety disorders; prescription-only
Studied ranges, not dosing advice. Not medical advice — talk to a clinician. doseroutine.com/library/venlafaxine
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Venlafaxine — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/venlafaxine
What compounds are similar to Venlafaxine?
Others in the medication category or studied for the same goals.